Melinta Therapeutics (MLNT) is a pharmaceutical company specialising in the development of treatments for bacterial infections. On Wednesday, June 19, we saw a huge spike in the stock price from $2 to over $6 at one point on news that the FDA had accepted a supplemental New Drug Application ((SNDA)) for priority review for MLNT's BAXDELA (delafloxacin) drug to include patients with community-acquired bacterial pneumonia ((CABP)). Rather than being anything ground-breaking, however, it is my view that this news was to be expected, and the obscene market reaction to it is largely due to misunderstanding